Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Moolec Science's Enterprise Value for the quarter that ended in Dec. 2025 was $74.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Moolec Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-111.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science EV-to-EBIT Related Terms
Moolec Science EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Moolec Science's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Moolec Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Moolec Science's EV-to-EBIT falls into.
Moolec Science's current Enterprise Value is $76.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Moolec Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-111.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science (MLEC) has a EV-to-EBIT of -0.68 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #999999 out of 372 companies in the Biotechnology industry.
Is Moolec Science's EV-to-EBIT too high?
Moolec Science's current EV-to-EBIT is -0.68. Based on the distribution chart, Moolec Science ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moolec Science has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's EV-to-EBIT compare to GNPX and ADIL?
According to the Biotechnology industry distribution chart, Moolec Science ranks #999999 out of 372 companies for EV-to-EBIT. This places Moolec Science in the lower half of its industry. The industry median EV-to-EBIT is 13.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Moolec Science and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moolec Science's current EV-to-EBIT is -0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.04 — trading 91.7% below its estimated fair value. The current EV-to-EBIT is -0.68. Moolec Science's overall GF Score™ is 44/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Moolec Science (MLEC), the current EV-to-EBIT is -0.68 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.04 is trading 91.7% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
EV-to-EBIT: -0.68
GF Value™: $84.84 vs. price of $7.04 (91.7% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
44GF Score
Get the complete analysis for MLEC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
